Genenta Science S.p.A.: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on May 2, 2022 and accepted by EDGAR at Apr 29, 2022, 21:20 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2021-01-01 to 2021-12-31 | EUR 3.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −EUR 5.7m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2021-01-01 to 2021-12-31 | −EUR 5.5m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | −EUR 0.37 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −EUR 7.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | EUR 9.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-12-31 | $25.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | EUR 38.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | EUR 40.0m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | EUR 1.1m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2021-12-31 | EUR 38.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-011671. Last ingested by Listed: Nov 2, 2026, 06:07 ET. Listed shows no prices and gives no investment advice.